Surveillance for acute viral hepatitis--United States, 2006.
In the United States, acute viral hepatitis most frequently is caused by infection with three viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV). These unrelated viruses are transmitted through different routes and have different epidemiologic profiles. Safe and effective vaccines have been available for hepatitis B since 1981 and for hepatitis A since 1995. No vaccine exists against hepatitis C. Cases in 2006, the most recent year for which data are available, are compared with those from previous years. Cases of acute viral hepatitis are reported voluntarily to CDC by state and territorial epidemiologists via CDC's National Notifiable Disease Surveillance System (NNDSS). Reports are received electronically via CDC's National Electronic Telecommunications System for Surveillance (NETSS). During 1995-2006, hepatitis A incidence declined 90% to the lowest rate ever recorded (1.2 cases per 100,000 population). Declines were greatest among children and in those states where routine vaccination of children was recommended beginning in 1999. An increasing proportion of cases occurred in adults. During 1990-2006, acute hepatitis B incidence declined 81% to the lowest rate ever recorded (1.6 cases per 100,000 population). Declines occurred among all age groups but were greatest among children aged <15 years. Following a peak in the late 1980s, incidence of acute hepatitis C declined through the 1990s; however, since 2003, rates have plateaued, with a slight increase in reported cases in 2006. In 2006, as in previous years, the majority of these cases occurred among adults, and injection-drug use was the most common risk factor. The results documented in this report suggest that implementation of the 1999 recommendations for routine childhood hepatitis A vaccination in the United States has reduced rates of infection and that universal vaccination of children against hepatitis B has reduced disease incidence substantially among younger age groups. Higher rates of hepatitis B continue among adults, particularly males aged 25-44 years, reflecting the need to vaccinate adults at risk for HBV infection. The decline in hepatitis C incidence that occurred in the 1990s was attributable primarily to a decrease in incidence among injection-drug users. The reasons for this decrease were unknown but likely reflected changes in behavior and practices among injection-drug users. The expansion in 2006 of recommendations for routine hepatitis A vaccination to include all children in the United States aged 12-23 months is expected to reduce hepatitis A rates further. Ongoing hepatitis B vaccination programs ultimately will eliminate domestic HBV transmission, and increased vaccination of adults with risk factors will accelerate progress toward elimination. Prevention of hepatitis C relies on identifying and counseling uninfected persons at risk for hepatitis C (e.g., injection-drug users) regarding ways to protect themselves from infection and on identifying and preventing transmission of HCV in health-care settings.